VVOS Vivos Therapeutics, Inc.
$0.12▼ -6.08%
Healthcare
Other
Volume 377.7K
Avg Volume (10D) 14.69M
Key Metrics & Fundamentals
Market Cap
$4.15M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.12 - 2.88
% vs 50 MA
-26.48%
% vs 200 MA
-83.20%
RSI-14
35.1
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.37
Free Cash Flow
-$3.56M
Gross Rev
$5.15M
Gross Profit
$2.95M
EBITDA
-$4.31M
COGS
$2.20M
Operating Exp
$7.78M
Operating Income
-$4.83M
EBIT
-$4.83M
Pretax Income
-$5.52M
Net Income
-$5.48M
EPS (Diluted)
-0.31
Price & Volume History
Loading chart…
Recent News
Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard
GlobeNewswire · Oct 21, 2026 7:00 AM ET
SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
ACCESS Newswire · Oct 20, 2026 11:40 AM ET
BC-Most Active Stocks
Associated Press · Oct 20, 2026 10:30 AM ET
Vivos Therapeutics Buys 11% of SOD Sciences, Gains 50% Stake in Diagnostic Test
MT Newswires · Oct 19, 2026 5:54 PM ET
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
GlobeNewswire · Oct 19, 2026 5:01 PM ET
Vivos to buy 50% stake in SOD Sciences’ pseudohypoxia test
Medical Device Network · Oct 16, 2026 7:12 AM ET
Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
GlobeNewswire · Oct 15, 2026 8:45 AM ET
Vivos Therapeutics Targets $3.6 Million in Annual Cost Reductions as Revenue Growth Initiatives Accelerate
InvestorsHub · Sep 29, 2026 10:42 AM ET
BC-Most Active Stocks
Associated Press · Sep 29, 2026 10:30 AM ET
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
GlobeNewswire · Sep 29, 2026 8:45 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See VVOS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.